Citigroup Maintains Neutral on Alight, Lowers Price Target to $16
Citigroup analyst Peter Christiansen maintains Alight (NYSE:ALIT) with a Neutral and lowers the price target from $20 to $16.
Read original at benzingaStocks · News reference
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday
The text discusses recent gains in the stock market, particularly for companies like Napco Security Technologies and SuperX AI Technology. US stocks were mixed, with the Dow Jones index gaining 150 points. Napco Security Technologies rose after better-than-expected results. Other big gainers include SuperX AI, Evolution Metals, and Cleveland-Cliffs.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 2:22 PM
- Checked
- Aug 24, 2026, 2:22 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Alight shares are trading lower after the company reported Q2 financial results and issued Q3 sales guidance below estimates. Also, the company issued FY26 sales guidance below estimates.
Read original at benzingaAlight Q2 Adj. EPS $0.91 Beats $0.76 Estimate, Sales $511.000M Beat $497.011M Estimate
Alight (NYSE:ALIT) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.76 by 19.74 percent. This is a 54.5 percent decrease over earnings of $2.00 per share from the same
Read original at benzingaCrude Oil Down 3%; XPeng Shares Fall After Q2 Results
US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected loss and lower revenue outlook.
Read original at benzingaB of A Securities Initiates Coverage On Alvotech with Buy Rating, Announces Price Target of $7
Read original at benzingaAlvotech Announces $150M Licensing And Commercialization Agreement With Lotus Pharmaceutical Plus Milestone Payments For Durvalumab, Emicizumab Biosimilars In U.S. And Eight Asian Markets
Read original at benzinga